Avastin VEGF Binding Assays

BioOutsource offers a range of off-the-shelf Avastin VEGF binding assays to support Avastin biosimilar manufacture, process development, characterization and similarity studies. We offer industry leading Avastin comparability and Avastin characterization services and these can be adapted for your product, if necessary.

Avastin (bevacizumab) mediates its activity through the interaction with VEGF. Avastin (bevacizumab) binds this protein with high affinity and mediates a number of different outcomes including inhibition of proliferation and migration, and the induction of apoptosis, amongst others. Therefore VEGF binding by Avastin, as with all antibody-antigen interactions, represents one of the key quality attributes of the Avastin (bevacizumab) molecule.

VEGF binding assays can be performed using a wide variety of different assay platforms and on each platform, these VEGF binding assays can be conducted using different binding assay designs. BioOutsource has developed the following Avastin VEGF binding assays:

Avastin VEGF Binding ELISA by Electrochemiluminescence (MSD)

BioOutsource offers Avastin VEGF binding assays using an upgraded version of the traditional ELISA on the Mesoscale Discovery (MSD) platform to report the relative binding of biosimilar and innovator Avastin material to cell-associated VEGF as a percentage of a designated reference lot with comprehensive parallelism assessments.

Avastin VEGF Binding by SPR

BioOutsource has improved the Avastin VEGF binding ELISA and offers an enhanced VEGF binding assay that significantly increases the understanding of the Avastin VEGF binding during comparability studies. We are pleased to offer the Avastin VEGF binding assay using surface plasmon resonance with the Biacore T-200 reporting full kinetic analysis including Affinity Constants (KD), with the association or “on” rate (Ka) and dissociation rate (Kd) or “off” rate. The data is also evaluated to generate relative binding and parallelism assessments.